Patents by Inventor Noelynn A. Oliver

Noelynn A. Oliver has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CONNECTIVE TISSUE GROWTH FACTOR ANTIBODIES
    Publication number: 20240076364
    Abstract: The present invention relates to antibodies that bind to CTGF. The antibodies are particularly directed to regions of CTGF involved in biological activities associated with fibrosis. The invention also relates to methods of using the antibodies to treat disorders associated with CTGF including localized and systemic fibrotic disorders including those of the lung, liver, heart, skin, and kidney.
    Type: Application
    Filed: December 20, 2022
    Publication date: March 7, 2024
    Applicant: FibroGen, Inc.
    Inventors: Al Y. LIN, Thomas B. NEFF, Noelynn A. OLIVER, William R. USINGER, Qingjian WANG, David A. YEOWELL
  • CONNECTIVE TISSUE GROWTH FACTOR ANTIBODIES
    Publication number: 20210230259
    Abstract: The present invention relates to antibodies that bind to CTGF. The antibodies are particularly directed to regions of CTGF involved in biological activities associated with fibrosis. The invention also relates to methods of using the antibodies to treat disorders associated with CTGF including localized and systemic fibrotic disorders including those of the lung, liver, heart, skin, and kidney.
    Type: Application
    Filed: September 8, 2020
    Publication date: July 29, 2021
    Applicant: FibroGen, Inc.
    Inventors: Al Y. LIN, Thomas B. NEFF, Noelynn A. OLIVER, William R. USINGER, Qingjian WANG, David A. YEOWELL
  • CONNECTIVE TISSUE GROWTH FACTOR ANTIBODIES
    Publication number: 20190023778
    Abstract: The present invention relates to antibodies that bind to CTGF. The antibodies are particularly directed to regions of CTGF involved in biological activities associated with fibrosis. The invention also relates to methods of using the antibodies to treat disorders associated with CTGF including localized and systemic fibrotic disorders including those of the lung, liver, heart, skin, and kidney.
    Type: Application
    Filed: October 10, 2018
    Publication date: January 24, 2019
    Applicant: FibroGen, Inc.
    Inventors: Al Y. LIN, Thomas B. Neff, Noelynn A. Oliver, William R. Usinger, Qingjian Wang, David A. Yeowell
  • Connective Tissue Growth Factor Antibodies
    Publication number: 20160257740
    Abstract: The present invention relates to antibodies that bind to CTGF. The antibodies are particularly directed to regions of CTGF involved in biological activities associated with fibrosis. The invention also relates to methods of using the antibodies to treat disorders associated with CTGF including localized and systemic fibrotic disorders including those of the lung, liver, heart, skin, and kidney.
    Type: Application
    Filed: May 25, 2016
    Publication date: September 8, 2016
    Applicant: FibroGen, Inc.
    Inventors: Al Y. Lin, Thomas B. Neff, Noelynn A. Oliver, William R. Usinger, Qingjian Wang, David A. Yeowell
  • CONNECTIVE TISSUE GROWTH FACTOR ANTIBODIES
    Publication number: 20160024198
    Abstract: The present invention relates to antibodies that bind to CTGF. The antibodies are particularly directed to regions of CTGF involved in biological activities associated with fibrosis. The invention also relates to methods of using the antibodies to treat disorders associated with CTGF including localized and systemic fibrotic disorders including those of the lung, liver, heart, skin, and kidney.
    Type: Application
    Filed: April 20, 2015
    Publication date: January 28, 2016
    Inventors: AL Y. LIN, Thomas B. Neff, Noelynn A. Oliver, William R. Usinger, Qingjian Wang, David A. Yeowell
  • Connective tissue growth factor antibodies
    Patent number: 9034643
    Abstract: The present invention relates to antibodies that bind to CTGF. The antibodies are particularly directed to regions of CTGF involved in biological activities associated with fibrosis. The invention also relates to methods of using the antibodies to treat disorders associated with CTGF including localized and systemic fibrotic disorders including those of the lung, liver, heart, skin, and kidney.
    Type: Grant
    Filed: November 30, 2012
    Date of Patent: May 19, 2015
    Assignee: FibroGen, Inc.
    Inventors: Al Y. Lin, Thomas B. Neff, Noelynn A. Oliver, William R. Usinger, Qingjian Wang, David A. Yeowell
  • Methods for treatment of muscular dystrophy
    Patent number: 8771692
    Abstract: The present invention relates to methods and agents useful for treating muscular dystrophy. Methods and agents for treating various physiological and pathological features associated with muscular dystrophy are also provided.
    Type: Grant
    Filed: July 2, 2010
    Date of Patent: July 8, 2014
    Assignee: FibroGen, Inc.
    Inventors: Enrique Brandan, Roel Goldschmeding, Noelynn A. Oliver
  • Diabetic nephropathy therapies
    Patent number: 8314059
    Abstract: The present invention relates to methods and compounds for treating specific early stage aspects and late stage aspects of diabetic nephropathy. Methods and compounds for treating various physiological features associated with early stage and with late stage diabetic nephropathy are also provided.
    Type: Grant
    Filed: June 3, 2010
    Date of Patent: November 20, 2012
    Assignee: FibroGen, Inc.
    Inventors: Allan Flyvbjerg, Guangjie Guo, David Y. Liu, Thomas B. Neff, Noelynn A. Oliver, William R. Usinger, Qingjian Wang
  • Connective tissue growth factor antibodies
    Publication number: 20110091468
    Abstract: The present invention relates to antibodies that bind to CTGF. The antibodies are particularly directed to regions of CTGF involved in biological activities associated with fibrosis. The invention also relates to methods of using the antibodies to treat disorders associated with CTGF including localized and systemic fibrotic disorders including those of the lung, liver, heart, skin, and kidney.
    Type: Application
    Filed: November 10, 2010
    Publication date: April 21, 2011
    Applicant: FibroGen, Inc.
    Inventors: Al Y. Lin, Thomas B. Neff, Noelynn A. Oliver, William R. Usinger, Qingjian Wang, David A. Yeowell
  • Antibodies that bind to a portion of the VWC domain of connective tissue growth factor
    Patent number: 7871617
    Abstract: The present invention relates to antibodies that bind to a portion of the Von Willebrand's factor (VWC) domain of connective tissue growth factor (CTGF). The antibodies are particularly directed to regions of CTGF involved in biological activities associated with fibrosis. The invention also relates to methods of using the antibodies to treat disorders associated with CTGF including localized and systemic fibrotic disorders including those of the lung, liver, heart, skin, and kidney.
    Type: Grant
    Filed: June 9, 2008
    Date of Patent: January 18, 2011
    Assignee: FibroGen, Inc.
    Inventors: Al Y. Lin, Thomas B. Neff, Noelynn A. Oliver, William R. Usinger, Qingjian Wang, David A. Yeowell
  • Diabetic nephropathy therapies
    Publication number: 20100291098
    Abstract: The present invention relates to methods and compounds for treating specific early stage aspects and late stage aspects of diabetic nephropathy. Methods and compounds for treating various physiological features associated with early stage and with late stage diabetic nephropathy are also provided.
    Type: Application
    Filed: June 3, 2010
    Publication date: November 18, 2010
    Applicant: FibroGen, Inc.
    Inventors: Allan Flyvbjerg, Guangjie Guo, David Y. Liu, Thomas B. Neff, Noelynn A. Oliver, William R. Usinger, Qingjian Wang
  • Connective tissues growth factor antibodies
    Publication number: 20090017043
    Abstract: The present invention relates to antibodies that bind to CTGF. The antibodies are particularly directed to regions of CTGF involved in biological activities associated with fibrosis. The invention also relates to methods of using the antibodies to treat disorders associated with CTGF including localized and systemic fibrotic disorders including those of the lung, liver, heart, skin, and kidney.
    Type: Application
    Filed: June 9, 2008
    Publication date: January 15, 2009
    Applicant: FibroGen, Inc.
    Inventors: Al Y. Lin, Thomas B. Neff, Noelynn A. Oliver, William R. Usinger, Qingjian Wang, David A. Yeowell
  • Connective tissue growth factor antibodies
    Patent number: 7405274
    Abstract: The present invention relates to antibodies that bind to CTGF. The antibodies are particularly directed to regions of CTGF involved in biological activities associated with fibrosis. The invention also relates to methods of using the antibodies to treat disorders associated with CTGF including localized and systemic fibrotic disorders including those of the lung, liver, heart, skin, and kidney.
    Type: Grant
    Filed: June 1, 2004
    Date of Patent: July 29, 2008
    Assignee: FibroGen, Inc.
    Inventors: Al Y. Lin, Thomas B. Neff, Noelynn A. Oliver, William R. Usinger, Qingjian Wang, David A. Yeowell
  • Diabetic nephropathy therapies
    Publication number: 20050214294
    Abstract: The present invention relates to methods and compounds for treating specific early stage aspects and late stage aspects of diabetic nephropathy. Methods and compounds for treating various physiological features associated with early stage and with late stage diabetic nephropathy are also provided.
    Type: Application
    Filed: February 11, 2005
    Publication date: September 29, 2005
    Inventors: Allan Flyvbjerg, Guangjie Guo, David Liu, Thomas Neff, Noelynn Oliver, William Usinger, Qingjian Wang
  • Connective tissue growth factor antibodies
    Publication number: 20040248206
    Abstract: The present invention relates to antibodies that bind to CTGF. The antibodies are particularly directed to regions of CTGF involved in biological activities associated with fibrosis. The invention also relates to methods of using the antibodies to treat disorders associated with CTGF including localized and systemic fibrotic disorders including those of the lung, liver, heart, skin, and kidney.
    Type: Application
    Filed: June 1, 2004
    Publication date: December 9, 2004
    Inventors: Al Y. Lin, Thomas B. Neff, Noelynn A. Oliver, William R. Usinger, Qingjian Wang, David A. Yeowell
  • Methods for inhibiting ocular processes
    Publication number: 20030153524
    Abstract: The present invention relates to methods for inhibiting or preventing ocular processes associated with CTGF. Methods and agents for use in treating or preventing ocular disorders, methods for diagnosing ocular disorders and related kits, and methods for screening for agents for use in the present methods are also provided.
    Type: Application
    Filed: December 11, 2002
    Publication date: August 14, 2003
    Inventors: David R. Hinton, Shikun He, Noelynn A. Oliver